Skip to content
OpenCapital
Get started

Edgewise Therapeutics, Inc. EWTX Q4 2024 Annual earnings

Reported March 3, 2025 · Before market open

EPS-$0.42Miss by $0.03
EPS estimate-$0.39

Next report

Aug 6, 2026 (In 1 week)
EPS estimate-$0.48

Financials

Q4 2024

Income statement

See full
Operating income-$45.5M-34.5%
Net income-$39.7M-31.6%
EPS (diluted)-$0.42+10.6%

Balance sheet

See full
Cash & equivalents$41.7M-51.6%
Total debt$4.7M-12.5%
Total equity$459.2M+44.0%
Total assets$486.8M+43.2%

Cash flow

See full
Operating cash flow-$27.0M-0.5%
CapEx$274.0K+70.2%
Free cash flow-$27.2M-0.9%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$2.53B+257%
Enterprise value$2.49B+297%

Returns & leverage

See full
Return on equity-34.4%+5.7pp
Debt / equity0×0.0×
Current ratio19.9×+0.4×

Versus estimates

Diluted EPS

Q1 2026-$0.46Beat by $0.04Q4 2025-$0.47Miss by $0.04Q3 2025-$0.39Beat by $0.01Q2 2025-$0.34Beat by $0.08Q1 2025-$0.43Beat by $0.02
Q4 2024-$0.42Miss by $0.03

Ask the moment Edgewise Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Edgewise Therapeutics, Inc. report Q4 2024 earnings?
Edgewise Therapeutics, Inc. (EWTX) reported Q4 2024 earnings on March 3, 2025 before market open.
What were Edgewise Therapeutics, Inc.'s Q4 2024 revenue and EPS?
Edgewise Therapeutics, Inc. reported eps of $-0.42 for Q4 2024.
Did Edgewise Therapeutics, Inc. beat estimates in Q4 2024?
EPS missed the consensus estimate of $-0.39 by $0.03.
Where can I find Edgewise Therapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0001558370-25-002006) directly on SEC EDGAR. The filing index links above go to sec.gov.